NL-OMON56726尚未招募不适用
Optimizing carboplatin dosing using Computed Tomography derived body composition and serum creatinine - POPCORN study
Amphia Ziekenhuis0 个研究点目标入组 40 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 发起方
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •- Age 18 years or older
- •- Available contrast-enhanced enhanced CT-scan including L3 at baseline before
- •carboplatin treatment (at least of six weeks before start of therapy)
排除标准
- •- Conditions that affect hemostasis in a way that blood drawing is complicated
- •(to be assessed by a physician)
- •- Drugs that inhibit creatinine clearance in the kidneys, like cimetidine,
- •trimethoprim, pyrimethamine, and salicylates (>100 mg)
- •- A carboplatin target AUC of below 4 mg/mL*min
研究者
相似试验
已完成
不适用
Assessment and optimisation of carboplatin exposure in pediatric oncology patients using different markers of kidney functioMalignancy1002765510029149cancerNL-OMON37073Vrije Universiteit Medisch Centrum20
已完成
不适用
Pharmacokinetic analysis of carboplatin in postoperative patients with Stage I seminomapostoperative patients with Stage I seminomaJPRN-UMIN000013415agoya University Hospital10
Unknown
4 期
Validation of an Adjusted Dosing Algorithm of CarboplatinCancerNCT02103244Rijnstate Hospital24
已完成
不适用
The combination chemotherapy of carboplatin and TS-1 followed by the maintenance therapy of TS-1 in advanced non-small cell lung cancer. Phase 2 trial.JPRN-UMIN000025932niversity of Fukui25
进行中（未招募）
1 期
Dose-banding of carboplatin: Effect on area under the plasma concentration - time curve (AUC) compared with individualised dosing - Carboplatin blood levels with dose-banded” and individualised systemsConditions for which carboplatin is indicated for: 1. Advanced ovarian carcinoma of epithelial origin in: - first line therapy - second line therapy, after other treatments have failed. 2. Small cell carcinoma of the lung, in association with other chemotherapeutic agents.EUCTR2006-001094-15-GBOxford Radcliffe Hospitals NHS Trust (Cancer Research UK Medical Oncology Unit, Churchill Hospital)10